Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQB NASDAQ:PBM OTCMKTS:RSPI NASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQBAquaBounty Technologies$0.78-3.2%$0.79$0.47▼$1.94$3.11M1.18458,593 shs99,445 shsPBMPsyence Biomedical$5.15+5.1%$4.75$2.92▼$699.19$2.79M0.22113,472 shs11,278 shsRSPICortex Pharmaceuticals$0.00-53.3%$0.00$0.00▼$0.00$1.42M0.14376,106 shs24,224 shsSILOSilo Pharma$0.61+2.0%$0.62$0.41▼$4.50$2.69M0.292.36 million shs114,694 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQBAquaBounty Technologies-3.18%+5.13%-1.89%+21.72%-53.91%PBMPsyence Biomedical+5.10%+0.29%-6.28%+35.18%-97.14%RSPICortex Pharmaceuticals-53.33%-53.33%-65.00%-12.50%-66.67%SILOSilo Pharma+1.98%-0.24%+5.40%-43.29%-32.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQBAquaBounty Technologies0.6009 of 5 stars0.05.00.00.00.70.00.6PBMPsyence BiomedicalN/AN/AN/AN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASILOSilo Pharma0.7455 of 5 stars0.02.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQBAquaBounty Technologies 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/ARSPICortex Pharmaceuticals 0.00N/AN/AN/ASILOSilo Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQBAquaBounty Technologies$2.47M1.22N/AN/A$4.10 per share0.19PBMPsyence BiomedicalN/AN/A$1.88 per share2.74$11.83 per shareN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/ASILOSilo Pharma$70K39.20N/AN/A$1.12 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQBAquaBounty Technologies-$149.19M-$19.05N/A∞N/AN/A-111.70%-85.47%8/5/2025 (Estimated)PBMPsyence Biomedical$1.01MN/A0.00∞N/AN/AN/AN/AN/ARSPICortex Pharmaceuticals-$2.10MN/A0.00∞N/AN/AN/AN/AN/ASILOSilo Pharma-$4.39M-$1.17N/A∞N/A-6,420.83%-84.88%-61.81%8/12/2025 (Estimated)Latest RSPI, PBM, AQB, and SILO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AQBAquaBounty Technologies-$0.61$0.16+$0.77$0.11$0.20 millionN/A5/9/2025Q1 2025SILOSilo PharmaN/A-$0.23N/A-$0.23N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQBAquaBounty TechnologiesN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQBAquaBounty TechnologiesN/A0.540.54PBMPsyence BiomedicalN/A11.0411.04RSPICortex PharmaceuticalsN/AN/AN/ASILOSilo PharmaN/A4.734.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQBAquaBounty Technologies8.92%PBMPsyence Biomedical77.44%RSPICortex PharmaceuticalsN/ASILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipAQBAquaBounty Technologies2.20%PBMPsyence Biomedical3.60%RSPICortex Pharmaceuticals50.03%SILOSilo Pharma4.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQBAquaBounty Technologies1003.87 million3.78 millionNo DataPBMPsyence BiomedicalN/A570,000548,000N/ARSPICortex Pharmaceuticals2949.46 million474.45 millionNot OptionableSILOSilo Pharma24.48 million4.29 millionNot OptionableRSPI, PBM, AQB, and SILO HeadlinesRecent News About These CompaniesSilo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026July 7 at 9:13 AM | quiverquant.comQSilo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025July 7 at 8:15 AM | globenewswire.comSilo Pharma Faces Nasdaq Non-Compliance NoticeJuly 3, 2025 | msn.comSilo Pharma and Hoth Therapeutics plan joint venture for obesity treatmentJune 26, 2025 | investing.comSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market - MorningstarJune 26, 2025 | morningstar.comMSilo Pharma and Hoth Therapeutics to Form Joint Venture for VA-Developed Obesity Treatment - NasdaqJune 26, 2025 | nasdaq.comSilo Pharma Enters LOI for Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketJune 26, 2025 | jcnnewswire.comJSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketJune 25, 2025 | globenewswire.comHoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.June 25, 2025 | prnewswire.comSilo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | finanznachrichten.deSilo Pharma, Inc. Receives Notice of Allowance for Patent Strengthening SPC-15 Treatment for PTSDJune 11, 2025 | quiverquant.comQSilo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | globenewswire.com16 Companies Announced A Bitcoin Treasury Last Week: ReportJune 9, 2025 | coingape.comCSilo Pharma, Inc. Approves $1 Million Bitcoin Purchase as Treasury Reserve AssetJune 7, 2025 | nasdaq.comSilo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetJune 5, 2025 | globenewswire.comSilo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War DoctrineJune 2, 2025 | newsfilecorp.comNSilo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 23, 2025 | finanznachrichten.deSilo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drugMay 21, 2025 | msn.comSilo Pharma, Inc. Partners with Resyca BV for SPC-15 Drug-Device Study Aimed at PTSD TreatmentMay 21, 2025 | quiverquant.comQSilo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRSPI, PBM, AQB, and SILO Company DescriptionsAquaBounty Technologies NASDAQ:AQB$0.78 -0.03 (-3.18%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$0.77 -0.01 (-1.16%) As of 07/8/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.Psyence Biomedical NASDAQ:PBM$5.15 +0.25 (+5.10%) Closing price 07/8/2025 03:36 PM EasternExtended Trading$5.14 -0.02 (-0.29%) As of 07/8/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Cortex Pharmaceuticals OTCMKTS:RSPI$0.0007 0.00 (-53.33%) As of 07/8/2025 03:53 PM EasternRespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.Silo Pharma NASDAQ:SILO$0.61 +0.01 (+1.98%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$0.62 +0.00 (+0.41%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
